Here’s how analysts see Verastem, Inc. (NASDAQ:VSTM) after this past week.

October 13, 2018 - By Hugh Holland

Investors sentiment increased to 2.07 in Q2 2018. Its up 0.91, from 1.16 in 2018Q1. It is positive, as 15 investors sold Verastem, Inc. shares while 15 reduced holdings. 36 funds opened positions while 26 raised stakes. 30.86 million shares or 129.37% more from 13.46 million shares in 2018Q1 were reported.
First Allied Advisory reported 35,000 shares stake. Manufacturers Life Insur The stated it has 41,994 shares. Ameriprise Inc accumulated 0% or 167,139 shares. Bnp Paribas Arbitrage Sa holds 1,728 shares or 0% of its portfolio. Moreover, Ameritas Investment has 0% invested in Verastem, Inc. (NASDAQ:VSTM) for 3,771 shares. Millennium Llc reported 172,934 shares. Massachusetts-based Bogle Investment Limited Partnership De has invested 0.13% in Verastem, Inc. (NASDAQ:VSTM). California-based First Republic Inv Management Inc has invested 0% in Verastem, Inc. (NASDAQ:VSTM). Advisory Net Limited Com has 22,025 shares for 0.01% of their portfolio. Blackrock reported 3.54 million shares. Geode Cap Mngmt Limited Liability Company invested in 507,234 shares or 0% of the stock. Gsa Cap Partners Limited Liability Partnership stated it has 109,554 shares or 0.04% of all its holdings. Voya Mgmt Ltd Company invested in 0% or 20,274 shares. Tiaa Cref Invest Lc reported 117,424 shares. Credit Suisse Ag accumulated 0% or 18,827 shares.

Verastem, Inc. (NASDAQ:VSTM) Ratings Coverage

Among 3 analysts covering Verastem (NASDAQ:VSTM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Verastem had 4 analyst reports since May 2, 2018 according to SRatingsIntel. The company was maintained on Thursday, May 10 by FBR Capital. The stock has “Buy” rating by FBR Capital on Friday, June 8. Below is a list of Verastem, Inc. (NASDAQ:VSTM) latest ratings and price target changes.

13/07/2018 Broker: BTIG Research Rating: Buy New Target: $17 Initiates Coverage On
08/06/2018 Broker: FBR Capital Rating: Buy New Target: $17.0000 Maintain
10/05/2018 Broker: FBR Capital Rating: Buy New Target: $17.0000 Maintain
02/05/2018 Broker: Seaport Global Rating: Buy New Target: $14 Initiates Coverage On

The stock decreased 9.31% or $0.58 during the last trading session, reaching $5.65. About 9.88 million shares traded or 233.94% up from the average. Verastem, Inc. (NASDAQ:VSTM) has risen 69.08% since October 13, 2017 and is uptrending. It has outperformed by 53.46% the S&P500.

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. The company has market cap of $415.80 million. The Company’s programs target the focal adhesion kinase and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. It currently has negative earnings. The Company’s lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.

More notable recent Verastem, Inc. (NASDAQ:VSTM) news were published by: Seekingalpha.com which released: “Verastem Oncology prices registered direct offering of $150M convertible notes” on October 12, 2018, also Seekingalpha.com with their article: “Verastem Tackles FDA Approval For Blood Cancer Drug” published on September 25, 2018, Seekingalpha.com published: “Verastem’s duvelisib beats Novartis’ Arzerra in late-stage blood cancer study; shares up 1% after hours” on October 04, 2018. More interesting news about Verastem, Inc. (NASDAQ:VSTM) were released by: Seekingalpha.com and their article: “Verastem: Post FDA Approval Investment Thesis” published on September 27, 2018 as well as Fool.com‘s news article titled: “Here’s Why Verastem Dropped Precipitously Today” with publication date: October 12, 2018.

Verastem, Inc. (NASDAQ:VSTM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>